Previous 10 | Next 10 |
− Program Recognizes Seven Patient Advocacy Groups Addressing Unmet Needs Among Three Rare Disease Communities − Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that seven patient advocacy groups will receive supporti...
Thanks to its newly announced COVID-19 antibody therapy candidates, Vir Biotechnology 's (NASDAQ: VIR) stock is still up more than 10% from the beginning of May and more than 180% from the start of the year. On top of its recent gains, there's reason to believe that Vir is positioned p...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET. Lumasiran is an investigational...
Alnylam Reports FDA Acceptance of Lumasiran Application Alnylam Pharmaceuticals, Inc. ( ALNY ) announced that the FDA has accepted its New Drug Application for Lumasiran. The drug candidate has also been awarded Priority Review status, which will reduce the review time from usual 10 mon...
Under Priority Review status, the FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application for lumasiran for the treatment of primary hyperoxaluria type 1 (PH1), a rare metabolic disorder caused by the overproduction of oxalate which leads to recurrent kidney...
— PDUFA Date Set for December 3, 2020 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for lumasiran, an i...
Introduction Think about it: the world is having a health crisis and what do we do? We created the largest global collapse since 1929! And as noted in prior columns , we are now at a point where nobody wanted to go: we must continually ask: do we continue the global “lockdownȁ...
Alnylam Announces Positive Long-Term Data from ONPATTRO Trial Alnylam Pharmaceuticals Inc. ( ALNY ) announced data from its Global Open Label Extension study of ONPATTRO for treating polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults. This interim 24 months data evaluated th...
As the coronavirus outbreak continues to spread throughout the world, investors have been loading up on shares of companies working on treatment or prevention. Gilead Sciences (NASDAQ: GILD) rose as much as 29% this year, but has since given up some gains and is now up 11%. Vir Biotech...
Investment Thesis Alnylam 1-year share price performance. Source: TradingView Alnylam ( ALNY ) is arguably the best known and most advanced developer of RNAi therapeutics - using small interfering RNA ("siRNA") to identify messenger RNA ("mRNA") and disrupt the process by which it encode...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...